Patrick AebischerPatrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse.
De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé.
En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne.
En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de lEPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016.
Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe quaux Etats-Unis.
Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs.
Les recherches quil poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.
Diego GhezziProf. Diego Ghezzi holds the Medtronic Chair in Neuroengineering at the School of Engineering at the Ecole Polytechnique Fédérale de Lausanne. He received his M.Sc. in Biomedical Engineering (2004) and Ph.D. in Bioengineering (2008) from Politecnico di Milano. From 2008 to 2013, he completed his postdoctoral training at Istituto Italiano di Tecnologia in Genova at the Department of Neuroscience and Brain Technologies; where he was promoted to Researcher in 2013. In 2015, he was appointed as Tenure-Track Assistant Professor of Bioengineering at the EPFL Center for Neuroprosthetics and Institute of Bioengineering.
Sean Lewis HillSean Hill is co-Director of Blue Brain, a Swiss national brain initiative, where he leads the Neuroinformatics division, based at the Campus Biotech in Geneva, Switzerland. He also directs the Laboratory for the Neural Basis of Brain States at the École Polytechnique Fédérale de Lausanne (EPFL). Dr. Hill served as the Executive Director (2011-2013) and Scientific Director (2014-2016) of the International Neuroinformatics Coordinating Facility (INCF) at the Karolinska Institutet in Stockholm, Sweden. Dr. Hill has extensive experience in building and simulating large-scale models of brain circuitry and has also supervised and led research efforts exploring the principles underlying the structure and dynamics of neocortical and thalamocortical microcircuitry. He currently serves in management and advisory roles on several large-scale clinical informatics initiatives around the world. After completing his Ph.D. in computational neuroscience at the Université de Lausanne, Switzerland, Dr. Hill held postdoctoral positions at The Neurosciences Institute in La Jolla, California and the University of Wisconsin, Madison, then joined the IBM T.J. Watson Research Center where he served as the Project Manager for Computational Neuroscience at Blue Brain until his appointment at the EPFL.
Gabriele GrenninglohSince 2017:Deputy Director, Brain Mind Institute, EPFL-SV2010 - 2014: Co-Manager, NCCR Synapsy, EPFL2005 - 2017:Deputy Head of the Laboratory of Neuroenergetics and Cellular Dynamics, EPFL-SV-LNDC and Deputy Director, Brain Mind Institute, EPFL-SV1997 - 2005:Group Leader, then Assistant Professor at the University of Lausanne1992 - 1997Senior Scientist, Glaxo Institute for Molecular Biology, Plan-les-Ouates, CH1989 - 1991Postdoc, then Research Geneticist, University of California at Berkeley, USA
Johannes GräffAcademic appointments
2013- Tenure Track Assistant Professor, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland, School of Life Sciences, Brain Mind Institute.
2009-2013 Postdoctoral fellow, Massachusetts Institute of Technology (MIT), Cambridge, USA, Picower Institute for Learning and Memory.
2009 Postdoctoral associate, Swiss Federal Institute of Technology (ETHZ), Zürich, Switzerland, Brain Research Institute.
Education
2009 PhD in Neurosciences, Swiss Federal Institute of Technology (ETHZ), Zürich, Switzerland, Department of Biology, Brain Research Institute.
2005 Diploma (M.Sc. equivalent) in Biological Sciences, University of Lausanne, Switzerland, Faculty of Biology and Medicine, Department of Ecology and Evolution.
1998 Matura, Gymnasium Type B, Kantonsschule am Burggraben St. Gallen, Switzerland.
Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
